<SEC-DOCUMENT>0001178913-19-002037.txt : 20190805
<SEC-HEADER>0001178913-19-002037.hdr.sgml : 20190805
<ACCEPTANCE-DATETIME>20190805080039
ACCESSION NUMBER:		0001178913-19-002037
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190805
FILED AS OF DATE:		20190805
DATE AS OF CHANGE:		20190805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Entera Bio Ltd.
		CENTRAL INDEX KEY:			0001638097
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38556
		FILM NUMBER:		19997598

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
		BUSINESS PHONE:		972-2-532-7151

	MAIL ADDRESS:	
		STREET 1:		KIRYAT HADASSAH, MINRAV BUILDING
		STREET 2:		FIFTH FLOOR
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9112002
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1923351.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 6.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><br>
  <div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">For the month of August 2019</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Commission file number: 001-38556</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">ENTERA BIO LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Exact Name of Registrant as Specified in Its Charter)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Hadassah<br>
      Minrav Building &#8211; Fifth Floor</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Jerusalem, Israel</font><br>
      (Address of principal executive office)</div>
    <div style="text-align: center; line-height: 1.25;">_____________________</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F &#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" noshade="noshade" align="center"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><u>CONTENTS</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">This report on Form 6-K of the registrant consists of a press release issued by the registrant on August 5, 2019, attached hereto as an exhibit and incorporated by reference herein.</div>
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;"><u>Exhibit</u></div>
    </div>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4b799478159a4834a66d07e38710a362" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 13.24%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit 99.1: <br>
              </a> </div>
          </td>
          <td style="width: 86.76%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">&#160;Press release dated August 5, 2019.</a></div>
          </td>
        </tr>

    </table>
    <div style="background-color: #FFFFFF; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><u>SIGNATURES</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z1d0ea9af25854d348f521ac44cff6484" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td colspan="2" style="width: 39.68%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">ENTERA BIO LTD.</div>
            <div style="line-height: 1.25;">(Registrant)</div>
          </td>
          <td style="width: 10.32%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 5.88%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: top;">&#160;</td>
          <td style="width: 10.32%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
          <td style="width: 5.88%; vertical-align: top; padding-bottom: 2px;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 33.8%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Dr. Phillip Schwartz</div>
          </td>
          <td style="width: 10.32%; vertical-align: top; padding-bottom: 2px;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 5.88%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: bottom;">
            <div style="line-height: 1.25;">Name: Dr. Phillip Schwartz</div>
          </td>
          <td style="width: 10.32%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 5.88%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: top;">
            <div style="line-height: 1.25;">Title: Chief Executive Officer</div>
          </td>
          <td style="width: 10.32%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 49.99%; vertical-align: top;">&#160;</td>
          <td style="width: 5.88%; vertical-align: top;">&#160;</td>
          <td style="width: 33.8%; vertical-align: top;">&#160;</td>
          <td style="width: 10.32%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;">Date: August 5, 2019</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 6.0.0.0
         Copyright 1995 - 2019 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">Entera Bio Appoints Adam Gridley as Chief Executive Officer</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="background-color: #FFFFFF; line-height: 1.25;">
          <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Jerusalem, Israel</font><font style="background-color: #FFFFFF; font-weight: bold;"> &#8211; Aug. 5, 2019</font><font style="background-color: #FFFFFF;">
              &#8211; Entera Bio Ltd. (Nasdaq: ENTX), </font>announced today the appointment of&#160;Adam Gridley&#160;as Chief Executive Officer, effective <font style="background-color: rgb(255, 255, 255); font-family: 'Times New Roman',Times,serif; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">immediately. Phillip</font><font style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-style: normal; font-variant: normal; text-transform: none;"> Sc</font>hwartz, Ph.D., former CEO of Entera since the Company&#8217;s inception in 2010, will
            continue with the Company as President of Research &amp; Development and Executive Vice President at Entera.</div>
          <div style="background-color: #FFFFFF; line-height: 1.25;">&#160;
            <div style="text-align: justify; line-height: 1.25;">&#8220;We are thrilled to have Adam, a highly accomplished pharmaceutical executive with proven business development and financial acumen, join Entera as CEO,&#8221; said Mr.&#160;Gerald Lieberman, Chairman
              of Entera&#8217;s Board of Directors. &#8220;Adam has a successful track record in developing and executing plans to grow start-ups to fully integrated global commercial organizations and building multiple executive leadership teams.&#160; His capabilities in
              business development and finance are highlighted by his involvement in over 15 strategic transactions and financings worth in excess of $600 million. The Board also thanks Dr. Schwartz for his many contributions and development progress since
              joining the Company in 2010.&#160; We are grateful for Phillip&#8217;s continued commitment and leadership in his new role as President of R&amp;D given his extensive development history and scientific expertise for our leading technology platform<font style="background-color: #FFFFFF;">.&#8221;</font></div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; line-height: 1.25;"><font style="background-color: #FFFFFF;">Mr. Gridley stated, </font>&#8220;I am delighted to lead Entera at this pivotal time, and believe there are substantial opportunities to create value both
              by leveraging the Company&#8217;s powerful oral delivery technology platform and by advancing our underlying therapeutic pipeline, for which we retain full global rights. We intend to continue the strategy of exploring strategic collaborations and
              licensing agreements with biotech and pharmaceutical partners for other large molecules and proteins, and building on the success of the strategic research collaboration signed with Amgen in 2018.&#8221;</div>
            <div style="line-height: 1.25">&#160;</div>
            <div style="text-align: justify; line-height: 1.25;">&#8220;For Oral human parathyroid hormone (&#8220;PTH&#8221;) in osteoporosis, the Company&#8217;s most advanced internal candidate, the positive&#160;guidance recently received from the&#160;FDA&#160;has provided clarity on the
              development path for this program, via the 505(b)(2) regulatory pathway,&#8221; Mr. Gridley continued. &#8220;I look forward to working with our talented team to advance this program rapidly, with the immediate priority of conducting a Phase 2a
              dose-ranging study, designed to inform the design of a Phase 3 study in osteoporosis.&#160; Further, we intend to maximize the value of our Hypoparathyroidism clinical candidate, which has Orphan Disease designation in the U.S. and E.U.&#8221;</div>
            <div style="line-height: 1.25">&#160;</div>
          </div>
        </div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Dr. Phillip Schwartz stated &#8220;I am honored to have served as CEO of Entera for almost a decade and very proud of the team we have built. I am excited to work together with Adam and am very
        confident&#160; passing&#160; the reigns to him with the broad experience in biotechnology and capital markets which he brings to the table. I look forward to myself and the team working with Adam to fully unlock the full potential of this platform with
        other companies, as we have started to show with our Amgen collaboration.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Prior to Entera, Mr. Gridley was President and CEO, and a Director of Histogenics Corporation, a public regenerative medicine company developing novel cell therapies and biologics for cartilage
        defects.&#160; He led Histogenics&#8217; $70 million IPO in December 2014, subsequently raised over $50 million of additional capital, and completed multiple strategic transactions including a $30 million collaboration with Intrexon to develop allogeneic cell
        therapies, and an $87 million Japanese license agreement with MEDINET for its Phase 3 biologic product<font style="background-color: #FFFFFF;">. Before joining Histogenics, Mr. Gridley served in several senior roles at Merz, a privately-held
          specialty healthcare company.&#160; </font>As Senior Vice President, Technical Operations at Merz, he led a variety of functions, including R&amp;D, Manufacturing, Quality Operations, Finance and IT for a portfolio of aesthetics, dermatology,
        neurology and OTC products that generated annual revenues of over $300 million<font style="background-color: #FFFFFF;">. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, which was acquired by Merz in
          2010. His responsibilities included all business development, investor relations, strategic planning, and R&amp;D functions, and he was part of the executive leadership team who led the Company&#8217;s $90 million IPO and subsequent acquisition by Merz
          for approximately $250 million in 2010. Mr. Gridley is currently a Director and Executive Chairman at LifeSprout, a Director of the Alliance for Regenerative Medicine (ARM), and a member of the board of advisors for Life Science Cares in Boston.&#160;
          Mr. Gridley holds a B.S. and a M.B.A. from the University of Denver.</font></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The terms of Mr. Gridley&#8217;s engagement are subject to the approval of the company's shareholders.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Entera Bio Ltd.</div>
      <div style="text-align: justify; line-height: 1.25;">Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other
        areas with significant unmet medical needs. The Company is initially applying its technology to develop an oral formulation of a human parathyroid hormone analog, Oral PTH (1-34), for treatment of hypoparathyroidism and osteoporosis.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Entera has developed a proprietary platform technology that enables oral delivery of biologicals and large molecule drugs, which are typically delivered via injections and or other non-oral
        pathways. However, oral drug delivery is the easiest method for self-administering medications, offers patients greater dosing flexibility, and has the highest patient acceptance and compliance rates as compared to all other routes of drug
        administration. The Company employs this technology for its own pipeline products and may enter into licensing agreements with biopharma companies for application of the technology to their proprietary compounds, such as the Amgen strategic
        research collaboration.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward Looking Statements</div>
      <div style="text-align: justify; line-height: 1.25;">This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends,"
        "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements.&#160;Forward-looking statements should not be read as a guarantee of future performance or results and may not be
        accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to
        future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.&#160;For a discussion of these and other risks that
        could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" in the Company's Registration Statement on Form F-1 and other
        filings with the Securities and Exchange Commission (SEC).&#160; Investors and security holders are urged to read these documents free of charge on the SEC's web site at&#160;http://www.sec.gov. The Company assumes no obligation to publicly update or revise
        its forward-looking statements as a result of new information, future events or otherwise.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
      <div style="text-align: justify; line-height: 1.25;">Bob Yedid</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;">646-597-6989</div>
      <div style="text-align: justify; line-height: 1.25;"><u>bob@lifesciadvisors.com</u></div>
      <div style="text-align: justify; line-height: 1.25;"><u> <br>
        </u></div>
      <div style="text-align: justify; line-height: 1.25;">
        <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" align="center"><u> </u></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
